secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2023-09-25T23:59:59+00:00
Accession:  0001193125-23-240931
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Viridian appoints Agios CMO Dr. Sarah Gheuens to Board of Directors
-------------------------------------------------------------------

- Board expanded from 5 to 6 directors; Gheuens appointed Class I director until 2025 annual meeting.
- Also appointed to Science and Technology Committee.
- Compensation: $46,000 annual retainer and option for 40,000 shares vesting over 3 years.
- Gheuens is CMO of Agios Pharmaceuticals (AGIO) and previously held roles at Biogen (BIIB).
- No arrangements, family relationships, or material interests requiring disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523240931/0001193125-23-240931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523240931/d533906d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-240931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer